Biosenic

FRA:BT1 (Belgium)  
€ 0.01 (-1.67%) Apr 22
At Loss
Market Cap:
€ 4.02M ($ 4.29M)
Enterprise V:
€ 28.54M ($ 30.41M)
Volume:
-
Avg Vol (2M):
21.11K
Also Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Biosenic ( ) from 2015 to Apr 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Biosenic stock (FRA:BT1) PE ratio as of Apr 23 2024 is 0. More Details

Biosenic (FRA:BT1) PE Ratio (TTM) Chart

To

Biosenic (FRA:BT1) PE Ratio (TTM) Historical Data

Total 1223
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Biosenic PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-12 At Loss
2024-03-15 At Loss 2024-01-11 At Loss
2024-03-14 At Loss 2024-01-10 At Loss
2024-03-13 At Loss 2024-01-09 At Loss
2024-03-12 At Loss 2024-01-08 At Loss
2024-03-11 At Loss 2024-01-05 At Loss
2024-03-08 At Loss 2024-01-04 At Loss
2024-03-07 At Loss 2024-01-03 At Loss
2024-03-06 At Loss 2024-01-02 At Loss
2024-03-05 At Loss 2023-12-29 At Loss
2024-03-04 At Loss 2023-12-28 At Loss
2024-03-01 At Loss 2023-12-27 At Loss
2024-02-29 At Loss 2023-12-22 At Loss
2024-02-28 At Loss 2023-12-21 At Loss
2024-02-27 At Loss 2023-12-20 At Loss
2024-02-26 At Loss 2023-12-19 At Loss
2024-02-23 At Loss 2023-12-18 At Loss
2024-02-22 At Loss 2023-12-15 At Loss
2024-02-21 At Loss 2023-12-14 At Loss
2024-02-20 At Loss 2023-12-13 At Loss
2024-02-19 At Loss 2023-12-12 At Loss

Biosenic (FRA:BT1) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.